FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2571208503> ?p ?o ?g. }

• W2571208503 endingPage "S439" @default.
• W2571208503 startingPage "S438" @default.
• W2571208503 abstract "MET alterations leading to exon 14 skipping occur in ∼4% of non-squamous non-small cell lung cancer (NSCLCs) and 20–30% of sarcomatoid lung carcinomas, resulting in MET activation and sensitivity to MET inhibitors in vitro.1–4 Crizotinib, initially developed as a MET inhibitor, is currently approved for the treatment of ALK-rearranged and ROS1-rearranged advanced NSCLC. We present crizotinib antitumor activity and safety data in patients (pts) with MET exon 14-altered advanced NSCLC. Advanced NSCLC pts positive for MET exon 14-alteration status determined locally by molecular profiling were enrolled into an expansion cohort of the ongoing phase I PROFILE 1001 study (NCT00585195) and received crizotinib at a starting dose of 250 mg BID. Objective responses were assessed using RECIST v1.0. As of the data cut-off of Feb 01, 2016, 21 pts with MET exon 14-altered NSCLC received crizotinib treatment (18 response-evaluable, 3 not yet evaluable). Median age was 68 y (range: 53−87). Tumor histology was: 76% adenocarcinoma, 14% sarcomatoid adenocarcinoma, 5% adenosquamous carcinoma, and 5% squamous cell carcinoma. Sixty-two percent (62%) of pts were former-smokers, 38% never-smokers, and there were no current smokers. Duration of treatment ranged from 0.2 to 12.2 mo, with 76% of pts (16/21) still ongoing. Five pts discontinued treatment (1 due to AE, 3 due to clinical or disease progression, and 1 preferred alternative treatment formulation). PRs were observed in 8 pts, for an objective response rate of 44% (95% CI: 22–69); 9 pts had stable disease. Median time to response was 7.8 weeks (range: 7.0–16.3), which was the approximate time of the scheduled first on treatment tumor scans for patients. Median progression-free survival could not be calculated. The most common (≥25%) treatment-related AEs (TRAEs) were edema (43%) diarrhea (33%), nausea (33%), vision disorder (33%), and vomiting (29%). Most TRAEs were grade 1/2 in severity and consistent with the known safety profile of crizotinib. Four grade 3 TRAEs (edema, bradycardia, anemia, and weight increased) and no grade 4 or 5 TRAEs were reported. Enrollment of pts with MET exon 14-altered NSCLC continues, and updated data will be available at the time of presentation. Crizotinib has clinically meaningful antitumor activity in pts with MET exon 14-altered advanced NSCLC. The drug has a tolerable AE profile, consistent with that previously reported for pts with ALK-rearranged or ROS1-rearranged advanced NSCLC. Further study of crizotinib in this pt population is warranted." @default.
• W2571208503 created "2017-01-13" @default.
• W2571208503 creator A5001058762 @default.
• W2571208503 creator A5012736318 @default.
• W2571208503 creator A5018740704 @default.
• W2571208503 creator A5022384270 @default.
• W2571208503 creator A5045419282 @default.
• W2571208503 creator A5052608673 @default.
• W2571208503 creator A5053365073 @default.
• W2571208503 creator A5059053635 @default.
• W2571208503 creator A5060033755 @default.
• W2571208503 creator A5061648315 @default.
• W2571208503 creator A5064382279 @default.
• W2571208503 creator A5078629724 @default.
• W2571208503 creator A5082517668 @default.
• W2571208503 creator A5087923582 @default.
• W2571208503 creator A5088474933 @default.
• W2571208503 date "2017-01-01" @default.
• W2571208503 modified "2023-09-30" @default.
• W2571208503 title "MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer" @default.
• W2571208503 doi "https://doi.org/10.1016/j.jtho.2016.11.512" @default.
• W2571208503 hasPublicationYear "2017" @default.
• W2571208503 type Work @default.
• W2571208503 sameAs 2571208503 @default.
• W2571208503 citedByCount "10" @default.
• W2571208503 countsByYear W25712085032018 @default.
• W2571208503 countsByYear W25712085032019 @default.
• W2571208503 countsByYear W25712085032021 @default.
• W2571208503 crossrefType "journal-article" @default.
• W2571208503 hasAuthorship W2571208503A5001058762 @default.
• W2571208503 hasAuthorship W2571208503A5012736318 @default.
• W2571208503 hasAuthorship W2571208503A5018740704 @default.
• W2571208503 hasAuthorship W2571208503A5022384270 @default.
• W2571208503 hasAuthorship W2571208503A5045419282 @default.
• W2571208503 hasAuthorship W2571208503A5052608673 @default.
• W2571208503 hasAuthorship W2571208503A5053365073 @default.
• W2571208503 hasAuthorship W2571208503A5059053635 @default.
• W2571208503 hasAuthorship W2571208503A5060033755 @default.
• W2571208503 hasAuthorship W2571208503A5061648315 @default.
• W2571208503 hasAuthorship W2571208503A5064382279 @default.
• W2571208503 hasAuthorship W2571208503A5078629724 @default.
• W2571208503 hasAuthorship W2571208503A5082517668 @default.
• W2571208503 hasAuthorship W2571208503A5087923582 @default.
• W2571208503 hasAuthorship W2571208503A5088474933 @default.
• W2571208503 hasBestOaLocation W25712085031 @default.
• W2571208503 hasConcept C121608353 @default.
• W2571208503 hasConcept C126322002 @default.
• W2571208503 hasConcept C143998085 @default.
• W2571208503 hasConcept C2775999482 @default.
• W2571208503 hasConcept C2776232967 @default.
• W2571208503 hasConcept C2776256026 @default.
• W2571208503 hasConcept C2776512503 @default.
• W2571208503 hasConcept C2777546739 @default.
• W2571208503 hasConcept C2779177807 @default.
• W2571208503 hasConcept C2779422266 @default.
• W2571208503 hasConcept C2779984678 @default.
• W2571208503 hasConcept C2780808757 @default.
• W2571208503 hasConcept C2781182431 @default.
• W2571208503 hasConcept C31760486 @default.
• W2571208503 hasConcept C535046627 @default.
• W2571208503 hasConcept C71924100 @default.
• W2571208503 hasConcept C81729549 @default.
• W2571208503 hasConceptScore W2571208503C121608353 @default.
• W2571208503 hasConceptScore W2571208503C126322002 @default.
• W2571208503 hasConceptScore W2571208503C143998085 @default.
• W2571208503 hasConceptScore W2571208503C2775999482 @default.
• W2571208503 hasConceptScore W2571208503C2776232967 @default.
• W2571208503 hasConceptScore W2571208503C2776256026 @default.
• W2571208503 hasConceptScore W2571208503C2776512503 @default.
• W2571208503 hasConceptScore W2571208503C2777546739 @default.
• W2571208503 hasConceptScore W2571208503C2779177807 @default.
• W2571208503 hasConceptScore W2571208503C2779422266 @default.
• W2571208503 hasConceptScore W2571208503C2779984678 @default.
• W2571208503 hasConceptScore W2571208503C2780808757 @default.
• W2571208503 hasConceptScore W2571208503C2781182431 @default.
• W2571208503 hasConceptScore W2571208503C31760486 @default.
• W2571208503 hasConceptScore W2571208503C535046627 @default.
• W2571208503 hasConceptScore W2571208503C71924100 @default.
• W2571208503 hasConceptScore W2571208503C81729549 @default.
• W2571208503 hasIssue "1" @default.
• W2571208503 hasLocation W25712085031 @default.
• W2571208503 hasOpenAccess W2571208503 @default.
• W2571208503 hasPrimaryLocation W25712085031 @default.
• W2571208503 hasRelatedWork W1589805911 @default.
• W2571208503 hasRelatedWork W1592240224 @default.
• W2571208503 hasRelatedWork W1666785645 @default.
• W2571208503 hasRelatedWork W2166589505 @default.
• W2571208503 hasRelatedWork W2571208503 @default.
• W2571208503 hasRelatedWork W2747108253 @default.
• W2571208503 hasRelatedWork W2896790022 @default.
• W2571208503 hasRelatedWork W3201550227 @default.
• W2571208503 hasRelatedWork W3207676954 @default.
• W2571208503 hasRelatedWork W4386099802 @default.
• W2571208503 hasVolume "12" @default.
• W2571208503 isParatext "false" @default.
• W2571208503 isRetracted "false" @default.
• W2571208503 magId "2571208503" @default.
• W2571208503 workType "article" @default.